Intravesical Therapy News and Research

RSS

Intravesical therapy is widely used in practice as an adjuvant treatment for early stage bladder cancer, following surgical transurethral resection. This is because it is a localized treatment that is administered directly into the bladder, leading to fewer systemic side effects but reduced efficacy on any metastases throughout the body.

Can selenium and vitamin E supplementation prevent recurrence and progression of non–muscle-invasive bladder cancer?

The use of vitamin E and selenium in preventing the recurrence and progression of NMIBC.

19 Oct 2023

Recommendations for treating bladder cancer during COVID-19 pandemic

Bladder cancer is associated with significant illness and mortality, particularly if treatment is delayed.

22 May 2020

Johns Hopkins Greenberg Bladder Cancer Institute awards grants for 10 bladder cancer research projects

A study of obesity and related metabolic changes on bladder cancer incidence and deaths, and a plan to use stem cells to grow novel urinary tubes are among 10 research projects awarded funding by the Johns Hopkins Greenberg Bladder Cancer Institute.

7 Mar 2016

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has successfully completed a Phase II trial, conducted under an IND, of Vesimune (TMX-101) in CIS (carcinoma in situ) of the bladder.

16 May 2014

Instillation of chemotherapy can minimize recurrence and progression of bladder cancer

Researchers at UCLA's Jonsson Comprehensive Cancer Center led by Dr. Karim Chamie have found that more intense surveillance and treatment of bladder cancer in the first two years after diagnosis could reduce the number of patients whose cancer returns after treatment and lower the disease's death rate. The study was published online ahead of press today in the journal Cancer.

6 Jun 2013

Patients with high-grade noninvasive bladder cancer do not receive recommended care

A new study has found that almost all patients with high-grade noninvasive bladder cancer do not receive complete care as recommended by current guidelines.

11 Jul 2011

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

Endo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for the treatment of a distinct form of bladder cancer. VALSTAR is the only FDA-approved intravesical therapy for patients with Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder for whom immediate removal of the bladder would be associated with unacceptable medical risks.

3 Sep 2009

More intensive treatment not associated with better outcomes in early bladder cancer

Patients with early bladder cancer who receive more intensive treatment within the first two years of diagnosis do not appear to have better survival than patients who receive less intensive treatment, according to a retrospective analysis published in the April 7 online issue of the Journal of the National Cancer Institute.

8 Apr 2009

New guidelines on non-muscle invasive bladder cancer

The AUA is pleased to announce their new Guideline on the Management of Nonmuscle Invasive Bladder Cancer. Each year, more than 60,000 people are diagnosed with bladder cancer, which has been linked to a number of risk factors, including cigarette smoking and exposure to hazardous chemicals.

13 Nov 2007

Intravesical Therapy News and Research

Further Reading